Incyte Corp
(MIL:1INCY)
€
66.84
0 (0%)
Market Cap: 13.69 Bil
Enterprise Value: 12.09 Bil
PE Ratio: 541.07
PB Ratio: 4.61
GF Score: 70/100 Incyte Corp at UBS Global Healthcare Conference Transcript
May 20, 2019 / 07:00PM GMT
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst
Okay. Good afternoon. My name is Carter Gould. I'm a senior biotech analyst here at UBS. Welcome to day 1 of the Global Healthcare Conference. I'm pleased to welcome Incyte to the stage. CEO and President, Hervé Hoppenot, is joining me. I also remind everyone if you'd like to ask questions through the app, please feel free. They will filter down to the iPad here and I will try to ask them. All right. Thank you very much for joining us.
HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO
© -
Thank you for inviting me.
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst
I don't know if you want to make some opening statements or you just begin to...
HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO
© -
I could. Yes, if it's helpful -- I mean basically, the situation for Incyte today is based on
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot